2.24 USD
▲+0.03+2.75%
盘后 2.27 +4.23%
2026-08-03
市值
$161.79M
市盈率
—
EPS
-1.85
股息率
—
52 周区间
1.19 – 3.60
成交量
283.35K
Beta
0.34
目标价
7.40
52W 低 1.1952W 高 3.60
价格走势
公司简介
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o...